Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01134575 · ClinicalTrials.gov registry record · Phase 2
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT01134575: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01134575 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01134575, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Interventions
- DRUG Rituximab
- DRUG CMC-544 (Inotuzumab Ozogamycin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-06-04 |
| Est. Completion | 2018-04-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01134575
The ClinicalTrials.gov registry entry for NCT01134575 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT01134575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01134575 about?
NCT01134575 is a clinical study titled "CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)". The goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
What is the current status of trial NCT01134575?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2010-06-04. Estimated completion is 2018-04-18.
What interventions are being tested in trial NCT01134575?
The interventions under investigation include: Rituximab (DRUG), CMC-544 (Inotuzumab Ozogamycin) (DRUG).
Who is sponsoring clinical trial NCT01134575?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.